Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

Journal of Experimental Medicine

Volumn 190, Issue 5, 1999, Pages 617-627

  Nishimura, Takashi ^a,c   Iwakabe, Kenji ^a   Sekimoto, Masashi ^a   Ohmi, Yasushi ^a   Yahata, Takashi ^a   Nakui, Minoru ^a   Sato, Takehito ^a   Habu, Sonoko ^a   Tashiro, Hiroyuki ^b   Sato, Marimo ^a   Ohta, Akio ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fujiya Co Ltd   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Cytokine; Th1; Th2; Tumor

Indexed keywords

LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; OVALBUMIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ADHESION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HELPER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY; TUMOR NECROSIS;

ANIMALS; ANTIGENS; CELL ADHESION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; TH1 CELLS; TH2 CELLS; TRANSFECTION;

EID: 0032858174     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.5.617     Document Type: Article

References (44)

1. Van der Bruggen, P., C. Traversari, P. Chomoez, C. Lurquin, E. De Plean, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science. 254: 1643-1647.
2. Li, Y., K.E. Hellströme, S.A. Newby, and L. Chen. 1996. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183:639-644.
3. + effector T cells. J. Exp. Med. 159:1295-1311.
4. Hamaoka, T., and H. Fujiwara. 1987. Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. Immunol. Today. 8:267-269.
5. Dranoff, G., and R.C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58:417-454.
6. Nishimura, T., K. Watanabe, T. Yahata, U. Lee, K. Ando, M. Kimura, I. Saiki, T. Uede, and S. Habu. 1996. Application of IL-12 to antitumor cytokine and gene therapy. Cancer Chemother. Phamacol. 38:S27-S34.
7. - T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122-1134.
8. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146:3235-3241.
9. + helper/killer T cells induced by anti-CD3 antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy. J. Immunol. 148:285-291.
10. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 278:1626-1629.
11. Fujimoto, T., R.B. Duda, A. Szilvasi, X. Chen, M. Mai, and M.A. O'Donnell. 1997. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J. Immunol. 158:5619-5626.
12. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
13. Gliboa, E., S.K. Nair, and H.K. Lyerly. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46:82-87.
14. Rosendahl, A., K. Kristensson, J. Hansson, L. Ohlsson, T. Kalland, and M. Dohlsten. 1998. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth. Int. J. Cancer. 76:274-283.
15. + helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy. J. Immunol. 154:1777-1785.
16. Mosmann, T.R., H. Cherwinski, M.W. Bond, M.A. Giedlin, and R.L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2357.
17. Mosmann, T.R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17: 138-146.
18. Trinchieri, G. 1995. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood. 84:4008-4027.
19. Nishimura, T., K. Watanabe, U. Lee, T. Yahata, K. Ando, M. Kimura, Y. Hiroyama, M. Kobayashi, S.H. Herrmann, and S. Habu. 1995. Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor. Immunol. Lett. 48:149-152.
20. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin 2 production by tumor bypasses T helper function in the generation of an antitumor response. Cell. 60:397-403.
21. Watanabe, Y., K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon y cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 86: 9456-9460.
22. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:503-512.
23. Allione, A., M. Consalvo, P. Nanni, P.L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M.P. Colombo, P. Dellabona, et al. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF-α, GM-CSF, and IFN-γ gene or admixed with conventional adjuvants. Cancer Res. 54:6022-6026.
24. + cytotoxic T-lymphocyte activation in mice. Cancer Res. 56:5005-5011.
25. lo thymocytes in vivo. Science. 250:1720-1723.
26. Nishimura, T., H. Yagi, Y. Uchiyama, and Y. Hashimoto. 1985. Lymphokine-activated cell-associated antigen involved in broad-reactive killer cell-mediated cytotoxicity. Cell. Immunol. 94:122-132.
27. Ohta, A., N. Sato, T. Yahata, Y. Ohmi, K. Santa, T. Sato, H. Tashiro, S. Habu, and T. Nishimuta. 1997. Manipulation of Th1/Th2 balance in vivo by adoptive transfer of antigen-specific Th1 or Th2 cells. J. Immunol. Methods. 209:85-92.
28. Nishimura, T., Y. Takeuchi, K. Urano, and S. Habu. 1991. Monoclonal antibody against actin cross-reacts with the Thy-1 molecule and inhibits LFA-1-dependent cell-cell interaction of T cells. J. Immunol 147:2094-2099.
29. Carbone, F.R., and M.J. Bevan. 1989. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J. Exp. Med. 169:603-612.
30. Nishimura, T., S.J. Burakoff, and S.H. Herrmann. 1987. Protein kinase C required for cytotoxic T lymphocyte triggering. J. Immunol. 139:2888-2891.
31. Tahara, H., H.Z. Zer, W.J. Storkus, I. Pappo, S.C. Watkins, U. Gubler, S.F. Walf, P.D. Robbins, and M.T. Lotze. 1994. Fibroblast genetically engineered to express IL-12 can suppress tumor growth and induce antitumor immunity to murine melanoma cell lines. Cancer Res. 54:182-189.
32. Fujiwara, H., S.C. Clark, and T. Hamaoka. 1996. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann. NY Acad. Sci. 795:294-309.
33. + T cells secreting Th1 or Th2 cytokines. Immunity. 2:271-279.
34. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
35. Masuda, Y., S. Mita, K. Sakamoto, T. Ishiko, and M. Ogawa. 1995. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells. Cancer Immunol. Immunother. 41:325-330.
36. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153:5659-5673.
37. Austrup, F., D. Vestweber, E. Borges, M. Lohning, R. Brauer, U. Herz, H. Renz, R. Hallmann, A. Scheffold, A. Radbruch, and A. Hamann. 1997. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature. 385:81-83.
38. Tanaka, Y., K. Kobayashi, A. Takahashi, I. Arai, S. Higuchi, S. Otomo, S. Habu, and T. Nishimura. 1993. Inhibition of inflammatory liver injury by a monoclonal antibody against lymphocyte function-associated antigen-1. J. Immunol. 151: 5088-5095.
39. Santamaria-Babi, L.F., R. Moser, M.T. Perez-Soler, L.J. Picker, K. Blaser, and C. Hauser. 1995. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1). J. Immunol. 154:1543-1550.
40. Nishimura, T., S. Ohta, N. Sato, Y. Togashi, M. Goto, and Y. Hashimoto. 1987. Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int. J. Cancer. 40:255-261.
41. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
42. Strassmann, G., C.O. Jacob, R. Evans, D. Beall, and M. Fong. 1992. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J. Immunol. 148:3674-3678.
43. + cytotoxic T lymphocytes from tumor-infiltrating lymphocytes. Jpn. J. Cancer Res. 86:135-139.
44. Ryffel, B. 1997. Interleukin-12: role of interferon-γ in IL-12 adverse effects. Clin. Immunol. Immunother. 83:18-20.